GPCRs, Radiopharma and the Rise of Functional Peptide Screening

Why It Matters

Functional screens de‑risk GPCR programs and accelerate translation, giving pharma a competitive edge in a crowded AI‑driven discovery space. The approach also expands the pipeline for radioligand therapies targeting cancer and neurological diseases.

Key Takeaways

• Eli Lilly paid $140 M upfront for Radionetics, securing future $1 B acquisition
• Functional peptide screens identify GPCR agonists, de‑risking programs faster
• Orphan GPCRs remain underexplored, offering new ligand opportunities
• Global peptide library services market valued ~$50 B, projected to grow

Pulse Analysis

The resurgence of functional peptide screening is reshaping how companies tackle G protein‑coupled receptors (GPCRs), a class that still accounts for roughly one‑third of all approved drugs. Unlike traditional binding assays, high‑throughput functional screens measure downstream signaling, allowing researchers to pinpoint true agonists that can activate orphan receptors and open novel therapeutic pathways. This capability is especially valuable in radiopharmaceutical development, where a peptide must both bind a tumor‑associated GPCR and deliver a radioactive payload. As AI‑driven design floods the market, functional readouts provide a tangible differentiator.

Big Pharma’s appetite for this approach is evident in recent transactions. In July 2024, Eli Lilly delivered a $140 million upfront payment to Radionetics Oncology, securing an exclusive option to acquire the biotech for $1 billion and gain access to its GPCR‑focused peptide platform. CROs such as Orbit Discovery, Charnwood Discovery, and Creative Bioarray are expanding service offerings, while the global peptide‑library screening market was estimated at $50 billion last year. These investments reflect confidence that functional peptide data can de‑risk early‑stage programs and accelerate go‑to‑market timelines.

Looking ahead, the convergence of peptide chemistry, high‑throughput functional assays, and AI‑enhanced modeling promises to unlock thousands of orphan GPCRs that have been historically neglected. Radioligand therapies, which rely on precise GPCR targeting, stand to benefit from more diverse peptide ligands, potentially improving efficacy against hard‑to‑treat cancers and crossing the blood‑brain barrier. However, scaling these screens requires robust automation and sophisticated data analytics to interpret complex signaling outputs. Companies that master this integration will likely set the pace in a crowded drug‑discovery landscape, turning functional peptide screening into a strategic moat.